These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 12820531)

  • 1. Understanding the age dependency of breast cancer biomarkers.
    Benz CC; Thor AD; Eppenberger-Castori S; Eppenberger U; Moore D
    Adv Gerontol; 2003; 11():117-20. PubMed ID: 12820531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers.
    Yau C; Fedele V; Roydasgupta R; Fridlyand J; Hubbard A; Gray JW; Chew K; Dairkee SH; Moore DH; Schittulli F; Tommasi S; Paradiso A; Albertson DG; Benz CC
    Breast Cancer Res; 2007; 9(5):R59. PubMed ID: 17850661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IMMUNOHISTOCHEMICAL AND BIOCHEMICAL ANALYSIS OF MAMMARY GLAND TUMOURS OF DIFFERENT AGE PATIENTS.
    Lykholat T; Lykholat O; Antonyuk S
    Tsitol Genet; 2016; 50(1):40-51. PubMed ID: 27266184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular Vesicles as Biomarkers and Therapeutic Targets in Breast Cancer.
    Sadovska L; Eglītis J; Linē A
    Anticancer Res; 2015 Dec; 35(12):6379-90. PubMed ID: 26637847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer survival and immunohistochemical similarities between primary and metastatic sites, as a surrogate marker for the cancer self-seeding.
    Kurbel S; Dmitrovic B; Tomas I; Kristek J; Bozac M
    Int J Biol Markers; 2012 Jul; 27(2):e167-8. PubMed ID: 22653743
    [No Abstract]   [Full Text] [Related]  

  • 6. Intrinsic Subgroups or Individual Biomarkers for Predicting Outcome of Metastatic Breast Cancer?
    Dowsett M
    JAMA Oncol; 2016 Oct; 2(10):1269-1271. PubMed ID: 27281312
    [No Abstract]   [Full Text] [Related]  

  • 7. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
    Sheikh UN; Cohen C; Siddiqui MT
    Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned.
    Santa-Maria CA; Gradishar WJ
    JAMA Oncol; 2015 Jul; 1(4):528-34; quiz 549. PubMed ID: 26181262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canadian external quality assurance program for breast cancer biomarkers.
    Terry J; Torlakovic E; Trotter M; Garratt J; Barnes P; Gown A; Pettigrew N; Gilks CB
    Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):486. PubMed ID: 20502320
    [No Abstract]   [Full Text] [Related]  

  • 10. HYAL1 overexpression is correlated with the malignant behavior of human breast cancer.
    Tan JX; Wang XY; Li HY; Su XL; Wang L; Ran L; Zheng K; Ren GS
    Int J Cancer; 2011 Mar; 128(6):1303-15. PubMed ID: 20473947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of breast cancer subtypes and patterns of metastasis on outcome.
    Kast K; Link T; Friedrich K; Petzold A; Niedostatek A; Schoffer O; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
    Breast Cancer Res Treat; 2015 Apr; 150(3):621-9. PubMed ID: 25783184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is initially metastatic breast carcinoma different from recurrent metastatic breast carcinoma?
    Dizdar O; Aksoy S; Altundag K
    Ann Oncol; 2009 Jan; 20(1):189; author reply 189-90. PubMed ID: 18820244
    [No Abstract]   [Full Text] [Related]  

  • 13. Annexin A3 is a mammary marker and a potential neoplastic breast cell therapeutic target.
    Zeidan B; Jackson TR; Larkin SE; Cutress RI; Coulton GR; Ashton-Key M; Murray N; Packham G; Gorgoulis V; Garbis SD; Townsend PA
    Oncotarget; 2015 Aug; 6(25):21421-7. PubMed ID: 26093083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolomics Biomarkers for Breast Cancer.
    Günther UL
    Pathobiology; 2015 Sep; 82(3-4):153-65. PubMed ID: 26330356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical profile of breast cancer with respect to estrogen receptor and HER2 status.
    Gloyeske NC; Woodard AH; Elishaev E; Yu J; Clark BZ; Dabbs DJ; Bhargava R
    Appl Immunohistochem Mol Morphol; 2015 Mar; 23(3):202-8. PubMed ID: 25356941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zinc isotopes: a novel approach to biomarkers of breast cancer?
    Larner F; Shousha S; Coombes RC
    Biomark Med; 2015; 9(4):379-82. PubMed ID: 25808441
    [No Abstract]   [Full Text] [Related]  

  • 17. Expression of TRAG-3 in breast cancer.
    Wu YZ; Zhao TT; Ni B; Zou LY; Liu HL; Zhu B
    Int J Cancer; 2003 Oct; 107(1):167-8. PubMed ID: 12925976
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative proteomics of primary breast carcinomas and lymph node metastases outlining markers of tumor invasion.
    Milioli HH; Santos Sousa K; Kaviski R; Dos Santos Oliveira NC; De Andrade Urban C; De Lima RS; Cavalli IJ; De Souza Fonseca Ribeiro EM
    Cancer Genomics Proteomics; 2015; 12(2):89-101. PubMed ID: 25770193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer biology and ethnic disparities in breast cancer mortality in new zealand: a cohort study.
    Seneviratne S; Lawrenson R; Scott N; Kim B; Shirley R; Campbell I
    PLoS One; 2015; 10(4):e0123523. PubMed ID: 25849101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo.
    Ziegler E; Hansen MT; Haase M; Emons G; Gründker C
    Breast Cancer Res Treat; 2014 Nov; 148(2):269-77. PubMed ID: 25292421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.